Evaluation of Current Errors Within the Administration of Phosphodiesterase-5 Inhibitors After More Than 10 Years of Use

Romero-Otero, Javier; Gómez, Borja García; Polo, J. Medina; Alcaide, Estíbaliz Jiménez; Cruz, E. Garcia; Font, Andrea Sallent; Antolín, Alfredo Rodríguez

doi:10.1016/j.urology.2014.02.016

Cited by 15 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between three and six months, the expectation to be prescribed a medication, the expectation that sexual function would be restored to normal and the expectation that the medication was the best treatment for ED all decreased. This suggests an ongoing loss of confidence in the drug despite improving erectile function, and may provide some explanation for the reported high discontinuation rates for PDE5Is [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction

Louizos

Knight

2015

Pharmacy

View full text Add to dashboard Cite

It has been reported that patients frequently discontinue treatment for erectile dysfunction (ED) with phosphodiesterase type 5 inhibitors (PDE5Is) despite apparently good therapeutic results. Because expectations have been shown to affect patients’ appraisals of many drugs, the purpose of this study was to determine whether expectations affected the therapeutic response to PDE5Is in men with apparent psychogenic ED. An unvalidated questionnaire was used to collect data on expectations in 80 men commencing PDE5I therapy, and after three and six months of treatment. At the same time, subjects completed the International Index of Erectile Function (IIEF), the Sexual Excitation/Inhibition Scale (SIS/SES) and Beck’s Depression Inventory (BDI). No evidence of an effect on expectations on changes in IIEF or BDI scores could be identified. Although changes in IIEF, and BDI scores from recruitment to three months were indicative of improved sexual function and less depression, scores for most items on the expectations scale decreased, suggesting that expectations were not being met. The items for which scores decreased were the expectation to be prescribed a drug, that the drug would restore the sexual function to normal, would work within 30 minutes of administration, improve patients confidence to engage in sexual activity, and that the medication was the best treatment for ED across the three data collection points. The findings of this study indicate that improvements in erectile function did not translate into changes in medication expectations that suggested user satisfaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction

Louizos

Knight

2015

Pharmacy

View full text Add to dashboard Cite

show abstract

“…Additionally, no association with the severity of ED has been observed in the gradually enhanced therapeutic effect with increasing dose [ 44 ], suggesting that an increased PDE5i dose may be key for improving efficacy in ED treatment. Furthermore, during early treatment, PDE5i nonresponders may not actually be nonresponders, and it is recommended to use PDE5is starting from the highest label-approved dose followed by down-titration to minimize the frustration caused by inadequate response due to inadequate drug dosage, thereby reducing the impact of psychological factors on the treatment [ 12 , 45 ]. Thus, increased doses may be an important strategy in PDE5i nonresponders.…”

Section: Approaches To Improve Ed In Pde5i Nonrespondersmentioning

confidence: 99%

Practical Approaches to Treat ED in PDE5i Nonresponders

et al. 2020

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a common sexual disorder in adult males and one of the most important factors affecting their quality of life and that of their partners. Although PDE5 inhibitors (PDE5is) are the first choice for improving erectile function, there is a substantial proportion of ED patients, termed PDE5i nonresponders, who do not respond to PDE5is. Because of the lack of effective therapies, these patients always have serious social and psychological problems due to ED, which should be addressed. Here, we review the available literature about ED and PDE5is and propose several strategies for mitigating ED in PDE5i nonresponders.

show abstract

Häufige Anwendungsfehler bei PDE-5-Hemmern

Kraus¹

2014

Uro-News

View full text Add to dashboard Cite

Evaluation of Current Errors Within the Administration of Phosphodiesterase-5 Inhibitors After More Than 10 Years of Use

Cited by 15 publications

References 15 publications

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction

Practical Approaches to Treat ED in PDE5i Nonresponders

Häufige Anwendungsfehler bei PDE-5-Hemmern

Contact Info

Product

Resources

About